Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Bright Minds Biosciences Inc (DRUG)

99 + Investors. Track Smart Money conviction in DRUG. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +9
Streak
8Q ▲
Buyers last Q
70%

Smart Money Signals — DRUG

Based on 100 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q
For 8 consecutive quarters, more hedge funds added DRUG than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
100 hedge funds hold DRUG right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +108% more funds vs a year ago

fund count last 6Q
+52 new funds entered over the past year (+108% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 70% buying

68 buying29 selling
Last quarter: 68 funds were net buyers (22 opened a brand new position + 46 added to an existing one). Only 29 were sellers (16 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.
⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 16 → 19 → 28 → 22. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 46% entered in last year

■ 5% conviction (2yr+) ■ 49% medium ■ 46% new
Only 5 funds (5%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
📈

Growing discovery — still being found

23 → 16 → 19 → 28 → 22 new funds/Q
New funds entering each quarter: 16 → 19 → 28 → 22. A growing number of institutions are discovering DRUG each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🌱

Early stage — 70% of holders entered in last year

■ 8% veterans ■ 22% 1-2yr ■ 70% new
Of 100 current holders: 70 (70%) entered in the past year, only 8 (8%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
📋

Smaller funds dominant — 17% AUM from top-100

17% from top-100 AUM funds
32 of 100 holders rank in the top 100 by AUM, but together hold only 17% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
5.3
out of 10
Moderate Exit Risk
Exit risk score 5.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — DRUG

In 2026 Q2, 68 hedge funds were net buyers of DRUG (22 opened a new position, 46 added to an existing one), while 29 reduced or exited (16 trimmed, 13 sold completely) — a 70% buyer ratio, indicating clear institutional accumulation. This marks 8 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +9 funds (more new holders than closures). Total institutional holders: 100.

Hedge Fund Ownership: DRUG

How many hedge funds hold DRUG — quarterly history vs. share price
Quarterly hedge fund ownership of DRUG vs. share price

Market Analysis: DRUG

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: DRUG

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

8 top-rated funds 4 high-conviction
Consensus
4.1
/ 10
breadth
×
Elite
3.5
/ 10
conviction
Hedge Fund Positioning: DRUG
99 + Investors

Track Smart Money conviction in DRUG. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 99 91 8.79%
13F Shares 9M 9M 1.37%
Total Value $653M $669M -2.41%
New Positions 22 28 -6
Increased Positions 45 43 +2
Closed Positions 14 11 +3
Reduced Positions 16 15 +1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: DRUG

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

99 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DRUG. Verified SEC 13F-HR filings.

QUARTER:
Top 25 DRUG holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Acuta Capital Partners, LLC 4.54% 92,745 $6.5M
2 Vivo Capital, LLC 3.57% 557,172 $39.1M
3 Cormorant Asset Management, LP 3.24% 900,000 $63.2M
4 B Group, Inc. 2.22% 67,500 $4.7M
5 KVP Capital Advisors, LP 1.64% 31,813 $2.2M
6 Parkman Healthcare Partners LLC 1.47% 205,053 $14.4M
7 Great Point Partners LLC 1.45% 109,603 $7.7M
8 Superstring Capital Management LP 1.35% 30,456 $2.1M
9 Braidwell LP 1.26% 483,822 $34.0M
10 Vestal Point Capital, LP 0.89% 545,000 $38.3M
11 MPM BioImpact LLC 0.87% 202,114 $14.2M
12 Sio Capital Management, LLC 0.86% 73,952 $5.2M
13 Ikarian Capital, LLC 0.67% 88,951 $6.2M
14 Artia Global Partners LP 0.50% 38,407 $2.7M
15 Exome Asset Management LLC 0.44% 10,110 $710K
16 Seven Grand Managers, LLC 0.34% 120,000 $8.4M
17 Platinum Investment Management Ltd 0.33% 19,127 $1.3M
18 Deerfield Management Company, L.P. 0.21% 283,000 $19.9M
19 AdvisorShares Investments LLC 0.21% 24,274 $1.7M
20 Driehaus Capital Management LLC 0.18% 433,377 $30.4M
21 Ra Capital Management, L.P. 0.16% 265,000 $18.6M
22 Eventide Asset Management, LLC 0.12% 130,013 $9.1M
23 Orbimed Advisors LLC 0.12% 93,000 $6.5M
24 ADAR1 Capital Management, LLC 0.10% 30,300 $2.1M
25 Seven Fleet Capital Management LP 0.07% 6,395 $449K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Bright Minds Biosciences Inc (DRUG)

What does the Smart Money Trend signal show for DRUG?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added DRUG than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for DRUG?

More buyers than sellers — 70% buying: Last quarter: 68 funds were net buyers (22 opened a brand new position + 46 added to an existing one). Only 29 were sellers (16 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for DRUG holders?

Smaller funds dominant — 17% AUM from top-100: 32 of 100 holders rank in the top 100 by AUM, but together hold only 17% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held DRUG?

Mostly new holders — 46% entered in last year: Only 5 funds (5%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →